By Ana S. Iltis, Grace Koster, Emily Reeves & Kirstin R. W. Matthews

Abstract

Recent advances in methods to culture…

Abstract

Scholars began reporting about this marketplace in the mid-2000s; however, there is no sign of it dissipating…

Scientists and members of the public exploring the controversial area of U.S. human embryo and embryoid research will find a complex and sometimes bewildering assortment of federal and state laws. The authors recommend additional guidance, but note slow progress in the development of embryo research policy.

Companies developing stem cell-based interventions should work with policymakers and patient advocates to address risks for current and future patients and to protect clinical research and the reputation of the field, write the authors. Read their full article in Cell & Gene Therapy Insights (free registration).

The intense marketing of unproven stem cell interventions has become an international health concern. The authors offer resources and suggestions for physicians seeking to effectively counsel patients and respond to their questions about various stem cell therapies.

The authors examine a proposal for new human embryo and embryoid guidelines, writing that before conducting any research beyond day 14, scientists must develop clear, thoughtful and culturally sensitive guidelines that include limitations and oversight procedures to ensure that science responds to societal needs and values.

This journal article explores why the public and stakeholders should help develop guidelines and policies governing scientific practices for controversial biomedical research issues, such as genetically editing human embryos.

The authors use household-level data and hourly industry data from Mexico to show how more efficient pricing mechanisms, combined with well-designed environmental regulations, can significantly improve economic, social and environmental outcomes.

The unproven stem cell intervention industry is a worldwide, direct-to-consumer market where clinics offer stem cells or stem cell-derived components to patients with little to no scientific or clinical basis. In this paper, the authors call for the establishment of a World Health Organization Expert Advisory Committee on Regenerative Medicine to tackle this issue and provide guidance. Stem Cell Reports: https://doi.org/10.1016/j.stemcr.2021.05.004